Keenova Therapeutics
Keenova Therapeutics reported a net loss of $96.1 million for the three months ended Sep 30, 2026.
Keenova Therapeutics filed a 10-Q with the SEC on Nov 10, 2026, 5:15 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001628280-26-072839
- Revenue was $549.5 million for the three months ended Sep 30, 2026.
- Net loss was $96.1 million for the three months ended Sep 30, 2026.
- Diluted EPS was -$2.43 for the three months ended Sep 30, 2026.
- Cash and equivalents were $1.09 billion as of Sep 30, 2026.
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
4 new legal mentions
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Operating income and margin | $75.4M | −$203.1M | +137% |
| Net income | −$96.1M | −$220.5M | +56% |
| Cash | $1.09B | $963.7M | +13% |
New legal mentions (4)
- Endo USA has responded to the subpoenas and is cooperating with the investigation.
- As of September 30, 2026, the Company's accrual for this loss contingency is approximately $8.5 million. +2 more paragraphs
- The defendants filed a motion for summary judgment, which the Court denied, and the case proceeded through a jury trial in September 2025.
- After considering numerous post-trial motions for judgment as a matter of law by both parties, the Court denied all pending Airgas motions and granted the Company's motion under 35 U.S.C. § 271(e)(4)(A) to redate the approval of Airgas' ANDA to until after the Company's litigated patents' expiration while vacating…